T

    Translational Development Acquisition Corp. Ordinary Shares (TDAC)

    Official site

    FINANCIAL SERVICES • SHELL COMPANIES • NASDAQ

    $10.84
    +0.00 (+0.05%)

    Market Cap: $209.31M

    Last updated: Aug 31, 2026 at 4:59 PM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$0.04N/AN/ABeat-37.1%
    Mar 26
    		$0.06N/AN/ABeat-13.1%
    Dec 25
    		$0.07N/AN/ABeat-
    Sep 25
    		$0.08N/AN/ABeat-
    Jun 25
    		$0.07N/AN/ABeat-
    Mar 25
    		$0.07N/AN/ABeat-
    Dec 24
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio42.08EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE0.00%ROIC16.25%
    Financial Health
    Debt/Equity-0.14xInterest CoverageN/A
    Current Ratio0.06xQuick Ratio0.06x
    Trading Statistics
    BetaN/AAvg Volume49.18K
    52-Week High$10.9552-Week Low$10.33

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.84
    SMA 20$10.85
    SMA 50$10.78
    SMA 200$10.61
    EMA 10$10.84
    EMA 20$10.83
    EMA 50$10.79
    EMA 200$10.63

    MACD

    Line: 0.01Signal: 0.02Hist: -0.01

    ADX

    ADX: 46.5+DI: 33.7-DI: 10.0

    Aroon & PSAR

    Aroon Up28.0
    Aroon DownN/A
    PSAR$10.90

    Bollinger Bands

    Upper Band$10.87
    Lower Band$10.82
    %B Position46%(Middle)
    Band Width0.37

    RSI (14-Day)

    Neutral
    58.2

    Momentum Oscillators

    Stoch %K16.7
    Stoch %D16.7
    Williams %R-71.4
    ROC (10d)-0.1%
    Momentum-0.01
    CCI (20d)-35.2
    MFI (14d)9.9

    Volatility Measures

    ATR (14d)$0.03(0.3%)
    StdDev (20d)0.01
    Hist Vol1.4%(Low)

    Volume Flow

    VWAP$10.85
    OBV6.3M
    AD Line1.2M
    CMF (20d)-0.244

    Volume Metrics

    Avg Vol (20d)51.0K
    Vol Ratio0.1x(Low)
    VWMA (20d)$10.85

    Pivot Points

    R3$10.84
    R2$10.84
    R1$10.84
    Pivot Point$10.84
    S1$10.84
    S2$10.84
    S3$10.84

    Advanced Oscillators

    TSI24.59
    Ultimate Osc41.2
    KST7.33

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$-553,290$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$-530,069$0$0$0N/A$0$0$0N/AN/A
    Gross Profit$0$0$-23,221$0$0$0N/A$0$0$0N/AN/A
    Operating Expenses$661,050$281,161$162,345$213,658$221,127$347,408$133,390$61,283$1,685$0$483,846$500
    R&D$0$0$0$0$0$0$0$0$0$0$0$0
    SG&A$661,050$281,161$162,345$213,658$221,127$347,408$133,390$61,283$1,685$0$483,846$500
    Operating Income$-661,050$-281,161$-162,345$-213,658$-221,127$-347,408$-133,390$-61,283$-1,685$0$-483,846$-500
    Interest Income$1.64M$1.61M$1.76M$1.87M$1.84M$1.83M$125,346$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$946,982$1.33M$1.60M$1.66M$1.62M$1.48M$-8,044$-61,283$-1,685$0$-483,846$-500
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$946,982$1.33M$1.60M$1.66M$1.62M$1.48M$-8,044$-61,283$-1,685$0$-483,846$-500
    EBITDA$-697,188$-281,161$-162,345$-213,658$-221,127$-347,408$-133,390$-61,283$-1,685$0$-483,846$-500
    EBIT$-697,188$-281,161$-162,345$-213,658$-221,127$-347,408$-133,390$-61,283$-1,685$0$-483,846$-500
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TDAC

    News

    Translational Development Investor Alert: Kahn Swick & Foti, LLC Investigates Translational Development Acquisition Corp. - TDAC

    Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger between Translational Development Acquisition Corp. (TDAC) and Prologium Holding Inc. The firm aims to determine if the merger is fair to Translational shareholders and whether the process leading to it was adequate. Shareholders are invited to contact KSF to discuss their legal rights regarding this transaction.

    Business Wire•8/20/26•
    Somewhat-Bearish

    Meteora Capital (TDAC) discloses 919,000-share beneficial stake in SPAC

    Meteora Capital, LLC and its managing member Vik Mittal, have reported a beneficial ownership of 919,000 shares of Translational Development Acquisition Corp. (TDAC) Class A Common Stock, which constitutes 6.27% of the class. This stake is held by funds and managed accounts where Meteora Capital acts as the investment manager, indicating shared voting and dispositive power over these shares. The filing specifies that this disclosure does not imply an admission of beneficial ownership for Section 13 purposes.

    Stock Titan•8/14/26•
    Neutral

    Translational Development Acquisition (TDAC): Linden Advisors reports 6.7% ownership stake

    Linden Advisors and related entities, including Siu Min (Joe) Wong, have reported a significant ownership stake in Translational Development Acquisition Corp. (TDAC). They beneficially own 1,150,000 Class A Ordinary Shares, which constitutes approximately 6.7% of the outstanding shares as of June 30, 2026. This disclosure was made via a SCHEDULE 13G/A SEC filing, detailing the shared voting and dispositive power among Linden Capital, Linden GP, Linden Advisors, and Mr. Wong.

    Stock Titan•8/14/26•
    Neutral

    Goldman Sachs Group (TDAC) discloses 1,056,879 TDAC shares in 7.2% stake

    The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a beneficial ownership of 1,056,879 Class A ordinary shares in Translational Development Acquisition Corp. (TDAC), representing a 7.2% stake. Both entities hold shared voting and shared dispositive power over these shares. The filing clarifies that Goldman Sachs disclaims beneficial ownership for securities held in certain client accounts or investment entities where interests are held by other persons.

    Stock Titan•8/12/26•
    Neutral

    ProLogium and TDAC (Nasdaq: TDAC) add $50M insider capital for battery SPAC

    ProLogium Holding Inc. and Translational Development Acquisition Corp. (TDAC) announced a secured commitment of $50 million in primary capital from existing ProLogium shareholders. This investment supports their proposed business combination, aiming to make ProLogium publicly listed. The funds will be used to scale battery production, advance construction of a gigafactory in France, and expand into new applications like data centers and aerospace.

    Stock Titan•7/28/26•
    Somewhat-Bullish

    Frequently Asked Questions About TDAC

    Does TDAC pay dividends?
    Translational Development Acquisition Corp. Ordinary Shares (TDAC) does not currently pay a regular dividend.
    What is TDAC's P/E ratio?
    Translational Development Acquisition Corp. Ordinary Shares has a price-to-earnings (P/E) ratio of 42.08.
    What is TDAC's market cap?
    Translational Development Acquisition Corp. Ordinary Shares (TDAC) has a market capitalization of $209.31M with a current stock price of $10.84.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In